Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Sigma Lithium draws fresh attention this week as a new institutional filing lands just as short-seller momentum shows its first signs of stalling.
The most newsworthy development is the Schedule 13G filed by L1 Capital Pty Ltd on 7 October, disclosing a 10.24% stake worth roughly 11.5 million shares. That makes L1 the second-largest disclosed holder after the controlling Brazilian entity A10 Investimentos, which holds 42.4% of shares. L1's filing is passive in form, a 13G rather than a 13D, so there is no activist agenda on the record. As with all 13D/G disclosures, the stake reflects a position as last disclosed around the 5% threshold, and the holder could trim below 5% without a further filing. Still, a fresh 10% position from an Australian fund manager in a Brazilian lithium miner is not routine. Van Eck Associates, which filed its own 13G in May disclosing 5.1%, remains on the register as well, adding to the picture of meaningful institutional accumulation at these prices.
Short positioning has ticked up on a one-month basis but appears to be stabilising. Short interest reached 3.4% of free float as of 6 October, up 24% over the past month, continuing the build flagged in the note published here on 1 October. The weekly pace has slowed, though: positions rose just 3.5% over the past week and edged down slightly on the day. That is a meaningful deceleration from the 30%-in-a-week pace seen at end-September. Borrow conditions remain relaxed. Cost to borrow is low at 0.75%, easing 8% on the week. Availability is ample at 394%, meaning there are nearly four shares available to borrow for every one currently shorted. The borrow market carries no sign of squeeze pressure.
Options sentiment has shifted noticeably toward call-side positioning. The put/call ratio dropped to 0.53 on Tuesday, below its 20-day average of 0.56 and close to the more bullish end of its recent range. That is a mild but clear rotation away from the defensive posture seen through late September, when the PCR ran above 0.67 for several consecutive sessions. The z-score of minus 0.34 puts the reading just below average, nothing extreme, but the direction of travel is worth noting alongside the L1 filing.
The Street remains split. BMO Capital's downgrade to Market Perform with a $10 target, filed just last week, sits in tension with JP Morgan's Overweight initiation at $14 from 18 September. The consensus sits at Hold across three ratings, with a mean price target of $11.33, about 17% above Tuesday's close of $9.71. The stock has lost 22% over the past month, making the target gap look wide. Factor scores do little to resolve the debate: analyst recommendation divergence ranks in the 94th percentile, reflecting genuine disagreement rather than consensus drift, while the short score of 48.7 is mid-table and has barely moved this week after rising steadily through September. Valuation is cheap on an EV/EBITDA basis at 5.6x, but the EPS surprise score at the 10th percentile suggests the company has a recent history of missing estimates.
Insider activity, while now three months old, adds a small supportive note. Director Marcelo Freire de Paiva made three open-market purchases in late June at prices between $11.70 and $13.30, totalling around $249,000. The stock has since fallen well below those entry points, which at minimum shows the purchases were not well-timed, but does confirm directional conviction at higher levels. No insider selling has been recorded in the window.
The next earnings print is scheduled for 13 November. The previous result, in August, produced a modest 0.9% one-day gain and a 5.6% five-day gain, a muted but positive reaction. With BMO's $10 target acting as a near-term ceiling for cautious investors and L1's 10% stake as a potential floor signal, the period between now and that November print is the one to watch.
See the live data behind this article on ORTEX.
Open SGML on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.